mortality in PV. It is the presenting symptom in 12 to tem. The incidence also depends on whether the patient 49016 ofpatients and the cause ofdeath in 20 to 40% ofpa has been treated and the modality of treatment. A notable tients. 1 All publications that described significant num finding is that the mean survival is greatly prolonged from bers ofpatients are listed in Table 1 . 1 -7 As can be seen, the 18 months to more than 10 years by treatment measures incidence of thrombosis depends on the age of the patient that lower the hematocrit value, in other words, by phle and whether there has been a prior thrombotic event.
botomy and use ofcytoreductive therapy, or both. It is also noteworthy in Table 1 that the incidence of thrombotic events varies widely. It is 12 to 49% in the presenting patient and is the cause of death in 20 to 40%. This is due to the complex nature of thrombogenesis in PV, which involves a multitude of factors. These factors are listed in Table 2 ,8-15 They include increased hemat ocrit, thrombo<,J'1:osis, impaired fibrinolytic activity, 13.16 platelet activation, leukocyte activation, endothelial dam age, interactions between platelets and endothelium, dif ferent modalities of therapy, and increased whole-blood viscosity. Among these factors, the increase in blood vis cosity, and hence the impairment of blood flow, is un questionably the major factor. In this article, the role of hyperviscosity will be reviewed,
The rheological principles ofwhole blood, a non Newtonian fluid, are discussed in detail by Baskurt and 
Impairment of fibrinolysis13
Increased activated protein C resistance 14 Increased markers of clotting {TAT complex, prothrombin fragment 1 +2, D-dimer) 15 Meiselman elsewhere in this issue!7 and will not be re peated here. In essence, the rate of flow of whole blood in the vessels depends on its viscosity. The latter varies with the shear rate, which is the flow velocity gradient between adjacent layers offluid and is measured in terms of inverse seconds (or S-I). In the human aorta at rest, for example, the shear rate at the wall of the vessel is high and is estimated to be around 100 8-1 . In contrast, in end-arterioles, capillaries, or venules, there are many variables such as nonparallel walls, pulsation in flow rate, and pockets oflow cellular concentration, the shear rate cannot be measured with precision but is estimated to be around 10 s-I,18 The factors affecting the whole blood viscosity relevant to PV will be discussed in the following sections.
INCREASED HEMATOCRIT
';! There is a clear relationship between the hematocrit (or packed cell volume) and the viscosity of whole blood. 8 This relationship varies with the shear rate ofblood flow. At low shear rate, the increase in hematocrit will show a greater rise in the viscosity than it will at high shear rate. Furthermore, the blood viscosity increases exponentially with a rise in the hematocrit value. Thus,' a relatively small increase in the hematocrit will produce a corre sponding logarithmic increase in viscosity. For example, in PV, the difference in the whole-blood viscosity be tween a hematocrit of 400Al and one of 60% may mean a change of viscosity of roughly two and a half times at high shear rate and close to three times at low shear rate. This hemodynamic principle has to be applied to the management of PV. The most important objective should be the reduction ofthe patient's hematocrit. In a recent survey of members of the American Society of Hematology, the common practice for treatment of PV is to attain a target hematocrit of 44%.19 This is well supported by a study showing that the frequency of thrombosis in PV patients increases sharply at a hemat ocrit greater than 44%.20 A high hematocrit may be present under many conditions other than PV. These conditions are listed in Table 3 . In these conditions, thrombosis is also a major cause of morbidity and mortality.21 However, thrombosis in secondary polycythemia has been studied less exten sively than it has been in PV, and detailed clinical data are lacking. The general assumption is that although in creaSed whole-blood viscosity is present in these condi tions, not all ofthem are associated with as high a throm botic risk as is seen in PV. This is because ofthe presence of other thrombophilic causes in PV, as mentioned ear lier. Part of the explanation is derived from the observa tion that treatment of PV by phlebotomy alone reduces the incidence of thrombosis by a smaller percentage than that seen when patients are treated with hydroxyurea (see data in Table 1 ). One of the differences in the effects of these two forms oftreatment could very well be the con current reduction ofplatelet counts with hydroyxurea.
Morphological Evidence of Hyperviscosity in Polycythemia Vera
Deformities developed in the capillaries following the onset of hyperviscosity can be observed directly in the nail bed capillaries, as first described by Brown and Gif fin.22 These vessels are elongated and packed with ag gregated red cells. In an experiment with animals aimed at elucidating this phenomenon, we induced increased hematocrit by dehydration. Cinematography of mesen teric capillaries revealed aggregated red cells in rouleaux formation. 23 These aggregated red cells stayed in the axial . . flow in the beginning, so that the plasma space between the aggregated red cells and the capillary wall is actually increased and can be distinguished readily (Fig. 1) . With increasing dehydration and greater loss ofthe plasma vol ume, this space will shrink further. The result is a lower ing of the shear rate in this region, creating an area of hyperviscosity. With the progression of dehydration and shrinkage of this space, the increase in viscosity is such that ultimately blood flow will decrease and stop. In PV, however, there is an increase in the total body plasma volume concurrent with the increase in hematocrit. This increase in plasma volume allows a greater space to be present between the red cells in the axial flow and the vessel wall, and may counteract some of the adverse ef fects of the increased viscosity.
Cerebral Blood Flow
In both PV and other forms of polycythemia, cerebral vascular occlusive disorders are more common than coro nary artery complications are. 2 4-26 Thus, cerebral blood flow in these disorders received much attention. 27 . 28 As anticipated from many physiological studies, cerebral .\ i blood flow decreases with an increase in viscosity. In polycythemic patients, in particular, a direct inverse re lationship exists between the cerebral blood flow and the whole-blood viscosity. 29 The role of oxygen delivered to the brain has also been well-studied. 30 There ar~ studies claiming that be cause a higher hemoglobin content in the blood carries an increased oxygen delivery to the brain, the cerebral blood flow is decreased for this reason alone. This, how ever, should not negate the importance of the role of in creased viscosity.
CLINICAL MANIFESTATIONS
Impaired capillary blood flow results in neurological man ifestations of PV. These include headache, dizziness, al tered mental status, confusion, and, in severe cases, coma. Visual changes also occur, with fundoscopic findings of hemorrhage; exudates, and the "link-sausages" appear ance of congested veins. The reduced flow in the retinal circulation may result in central retinal vein occlusion (Fig. 2) . Other neurological manifestations include pe ripheral neuropathy and myopathy. Dramatic relief of the neurological symptoms is often seen after reduction in the hematocrit by phlebotomy.
Thrombotic complications can occur in both ar teries and veins and manifest as stroke, myocardial in farction, deep vein thrombosis, or pulmonary embolism. The relative incidence of arterial thrombosis is 34% for cerebrovascular accidents, 13% for acute myocardial in farction, and 9% for peripheral arterial occlusion. The mortality rate associated with these complications is also high: 35%. Thrombosis may also occur in unusual sites, such as in the mesenteric arteries or veins and in the he patic vein. More than 10% of patients with Budd-Chiari syndrome were found to have Py'Jl There is often a lack of correlation between the platelet count and the throm bosis. Patients with normal platelet counts are at as much risk as those with thrombocythemia.
Paradoxically, patients with PV may also have in creased bleeding risk. Whether the increased viscosity contributes to the impaired vascular contractility and thus to increased bleeding is not clear. The reduction of hem a tocrit by phlebotomy, erythrocyte phereisis, or cytoreduc tive therapy can likewise correct the bleeding diathesis.
Hyperviscosity in Abnormal Red Blood Cell Aggregation
In capillaries, an unobstructed passage of red cells under physiological conditions occurs with discrete red cells and constant shape changes. Any alterations in the red cell's characteristics will interfere with the flow. Whole-blood viscosity depends on factors that cause red cells to aggre gate, and the latter depends on the red cell deformability or plasticity. At low shear rates, red cells are aggregated. The aggregation, however, is reversed, with an increase in the shear rates, so that at high shear rates, the red cells change from aggregates to discrete forms. The major fac tor controlling aggregation is the cell-to-cell adhesion, which is the cell surface charge or the Z potential, which keeps one cell apart from the other. This is decreased by changes in the ambient fluid, such as an increase in pro teins, as in the case of hypergammaglobulinemia, or an increase in fibrinogen concentration.
There are other factors that affect aggregation that are as yet unexplained, such as gravity. In vitro experi I ment STS 51-C carried out on the space shuttle Dis 1 covery revealed that aggregates are smaller at zero grav ity.J2 Increased red cell aggregation is easily demonstrated by microscopic examination of a coverslip preparation of blood; Figure 3 shows marked rouleaux formation of the red cells in a patient with an acquired dysfibrinogen emia whose fibrinogen induced increased red cell aggre gation. He presented with digital arterial occlusion and digital gangrene. Mter treatment that reduced the pa tient's fibrinogen level, the rouleaux diminished, with a dramatic relief ofthe ischemic symptoms. There are many clinical disorders in which rouleaux formation ofred cells is recognized (Table 4) .33-51 Many of these disorders are known to be associated with increased risk of thrombo sis. The thrombotic event may also be precipitated when a new hyperviscosity-inducing factor is added to an ex isting disorder. An illustrative example is given in the following case history. A woman presented with autoim mune hemolytic anemia with a high titer of cold hemag glutinin. Her red cells showed marked aggregation even at room temperature. When her hemolytic disease was refractory to immunosuppressive therapy with cyc1ophos phamide, her physician treated her with a full dose ofin travenous immunoglobulin (IVIG). Immediately after the administration, she lapsed into a coma and was trans ferred to our hospital. She was found to have developed generalized livedo reticularis (Fig. 4) . Aggressive plasma pheresis was started with a 3-L exchange with 5% albu min twice daily. On the second day, she regained con sciousness, and her livedo reticularis was resolving. Unfortunately, she then developed thrombotic occlusion of the vascular supply to her hypothalamus and suc cumbed to hyperpyrexia of 107°F. IVIG administration is known to induce a hyperviscosity state in the blood and may also cause red cell aggregation. Thus, the justi fication for its use in an existing hyperviscosity syndrome is questionable.
Another common clinical test that shows increased red cell aggregation is the erythrocyte sedimentation rate. Treatment of the underlying clinical disorder may also correct the increased red cell aggregation. Unfortunately, the rheological abnormalities in these conditions are not widely recognized by practicing clinicians.
Methods for Measuring Whole-Blood Viscosity
As discussed earlier in this article, the shear rate varies with different vessels of different sizes and flow rate. Unfortunately, the viscometer used in most clinical lab oratories employs the measurement of serum or plasma flow through a capillary tube under shear rates many times higher than those seen in vivo. Thus, the use of this method of estimation of viscosity in polycythemia is of little use. There is newer equipment that measures the viscosity ofwhole blood with a shear rate that ranges from 10 to 120 S-l. Results will more aptly be reflecting the in vivo viscosity. Hopefully, their use will be more popular in the near future.
Another measure of the attractive forces among the red cells is the yield stress. This measurement will provide an estimate of the aggregability ofred cells. These measurements are not available in clinical laboratories at present.
MANAGEMENT
Reduction of whole-blood viscosity is the primary aim in treating hyperviscosity in PV. This can be done by phlebotomy along with cytoreductive therapy, Phlebotomy This is a safe method and is most commonly employed, whether singly or in combination with cytoreductive therapy. It has been shown that in PV patients a hema Sickle cell traits47
Hereditary spherocytosis, elliptocytosis 48 
Babesia argentina infection 49
Plasmodium knowlesi infection 50 N-acetylneuraminic acid deficiency51 tocrit above 44% is associated with a steep rise in the incidence of thrombotic complication. 2o Hence, this value should be the objective of treatment. In women, a , lower hematocrit of 42% is recommended, and in preg nancy, an even lower value of 36% should be used. 1 In cases involving a PV patient with a high hematocrit and impending risk of thrombosis, bleed ing, or congestive heart failure, the removal of red cells may be accomplished more readily by erythrocyto pheresis. Detailed description of this technique is pro vided in another article in this issue. 52 The drawback of phlebotomy and of erythrocytopheresis includes re active thrompocytosis, logistical problems such as nec essary frequent visits, and the need for good venous access.
Cytoreductive Therapy with Chemotherapeutic Agents
The most commonly used drug is hydroxyurea. This is an antimetabolite and is cycle specific for S-phase of the cell cycle. The starting dose is usually 500 mg daily, with upward adjustment depending on the hematocrit value. It has few side effects. The thrombosis incidence fol lowing hydroxyurea therapy was shown to be much lower than when PV was treated with phlebotomy alone. 6 Other myelosuppressive agents include chlorambucil and buls ufan. The latter is no longer used because of complica tions of myelofibrosis. More recently, interferon-alpha was shown to be effective in suppressing erythropoiesis. However, its side effects and cost are important consid erations against its common use. 32p may provide the logistic advantage of requiring fewer visits to the physician, It is, however, rarely used today because of the leukemogenic potential and its effect of reducing the plasma volume. 1
CONCLUSION
Findings in the past two decades enable us to have an improved understanding of the pathophysiology of thrombogenesis in PV and other red cell disorders. The common denominator in the pathogenesis is the pres ence ofhyperviscosity. The clinical picture and the throm botic complications in these disorders can now be ex plained on the basis of the impaired blood flow as a result ofincreased whole-blood viscosity. These findings also provide the scientific basis for the management of these disorders.
